JP2012502965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502965A5 JP2012502965A5 JP2011527395A JP2011527395A JP2012502965A5 JP 2012502965 A5 JP2012502965 A5 JP 2012502965A5 JP 2011527395 A JP2011527395 A JP 2011527395A JP 2011527395 A JP2011527395 A JP 2011527395A JP 2012502965 A5 JP2012502965 A5 JP 2012502965A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- cancer
- saturated aliphatic
- nfκb
- abnormal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 125000001931 aliphatic group Chemical group 0.000 claims 23
- 102000011727 Caspases Human genes 0.000 claims 16
- 108010076667 Caspases Proteins 0.000 claims 16
- 230000002159 abnormal effect Effects 0.000 claims 16
- 230000011664 signaling Effects 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 206010061218 Inflammation Diseases 0.000 claims 14
- 230000004054 inflammatory process Effects 0.000 claims 14
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 12
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 12
- 206010006187 Breast cancer Diseases 0.000 claims 8
- 208000026310 Breast neoplasm Diseases 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 206010060862 Prostate cancer Diseases 0.000 claims 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 208000029742 colonic neoplasm Diseases 0.000 claims 8
- 230000006735 deficit Effects 0.000 claims 8
- 230000002779 inactivation Effects 0.000 claims 8
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 7
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 6
- 230000004913 activation Effects 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 210000000987 immune system Anatomy 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 208000020084 Bone disease Diseases 0.000 claims 4
- 206010065687 Bone loss Diseases 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 4
- 102000000589 Interleukin-1 Human genes 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 208000027067 Paget disease of bone Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 210000000270 basal cell Anatomy 0.000 claims 4
- 208000016738 bone Paget disease Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 201000005787 hematologic cancer Diseases 0.000 claims 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- -1 piperidino, piperazino, morpholino, thiomorpholino Chemical group 0.000 claims 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010023203 Joint destruction Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000010029 ameloblastoma Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 210000003298 dental enamel Anatomy 0.000 claims 2
- 208000010932 epithelial neoplasm Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 CN(C)Cc1cc(NS(c(cc2)c(*)cc2-c(c(F)c2)ccc2F)(=O)=O)ccc1 Chemical compound CN(C)Cc1cc(NS(c(cc2)c(*)cc2-c(c(F)c2)ccc2F)(=O)=O)ccc1 0.000 description 2
- SUOMABXIKRAHEZ-UHFFFAOYSA-N Cc(c(CCO)ccc1)c1NS(c(cc1)ccc1-c(ccc(F)c1)c1F)(=O)=O Chemical compound Cc(c(CCO)ccc1)c1NS(c(cc1)ccc1-c(ccc(F)c1)c1F)(=O)=O SUOMABXIKRAHEZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9827508P | 2008-09-19 | 2008-09-19 | |
| GB0817208.2 | 2008-09-19 | ||
| US61/098,275 | 2008-09-19 | ||
| GBGB0817208.2A GB0817208D0 (en) | 2008-09-19 | 2008-09-19 | Therapeutic apsap compounds and their use |
| PCT/GB2009/002223 WO2010032010A1 (en) | 2008-09-19 | 2009-09-18 | Aryl-phenyl-sulfonamide-phenylene compounds and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012502965A JP2012502965A (ja) | 2012-02-02 |
| JP2012502965A5 true JP2012502965A5 (enExample) | 2012-10-25 |
| JP5840492B2 JP5840492B2 (ja) | 2016-01-06 |
Family
ID=39951896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527395A Active JP5840492B2 (ja) | 2008-09-19 | 2009-09-18 | アリール−フェニル−スルホンアミド−フェニレン化合物とその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8207167B2 (enExample) |
| EP (1) | EP2349990B8 (enExample) |
| JP (1) | JP5840492B2 (enExample) |
| CA (1) | CA2736980C (enExample) |
| DK (1) | DK2349990T3 (enExample) |
| ES (1) | ES2675074T3 (enExample) |
| GB (1) | GB0817208D0 (enExample) |
| WO (1) | WO2010032010A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| RU2015124564A (ru) * | 2012-12-10 | 2017-01-12 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ БЕНЗОЛСУЛЬФОНАМИДА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ RORc |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| ES2899852T3 (es) * | 2014-12-17 | 2022-03-15 | Pimco 2664 Ltd | Compuestos de N-(4-hidroxi-4-metil-ciclohexil)-4-fenil-bencenosulfonamida y N-(-4-hidroxi-4-metil-ciclohexil)-4-(2-piridil)-bencenosulfonamida y su uso terapéutico |
| EP3438090A4 (en) * | 2016-03-31 | 2019-09-04 | FUJIFILM Toyama Chemical Co., Ltd. | NOVEL PROCESS FOR PRODUCING HYDROXAMIC ACID DERIVATIVE AND CORRESPONDING INTERMEDIATE |
| GB201813312D0 (en) * | 2018-08-15 | 2018-09-26 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| GB201905520D0 (en) | 2019-04-18 | 2019-06-05 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| WO2021047978A1 (en) | 2019-09-12 | 2021-03-18 | BASF Agro B.V. | Process for the preparation of α-methyl-[4-(nitro)-2-(trifluoromethyl)]-benzyl nitrate |
| CA3191223A1 (en) * | 2020-08-31 | 2022-03-03 | Alfonso Bellacosa | Methods of treating cancer |
| EP4431090A1 (en) | 2023-03-15 | 2024-09-18 | Istesso 1 Limited | Solfonamides acting as mitochondrial complex i modulator compounds |
| GB202308547D0 (en) | 2023-06-08 | 2023-07-26 | Istesso 2 Ltd | Tnf inhibitor combination therapies |
| GB202309515D0 (en) | 2023-06-23 | 2023-08-09 | Istesso 2 Ltd | JAK inhibitor and IL-6 inhibitor combination therapies |
| GB202315822D0 (en) | 2023-10-16 | 2023-11-29 | Istesso 3 Ltd | Anti-fibrotic combination therapeutics |
| GB202317050D0 (en) | 2023-11-07 | 2023-12-20 | Istesso 2 Ltd | Disease modifying anti-rheumatic drug combination therapies |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| GB2001307A (en) * | 1977-07-01 | 1979-01-31 | American Cyanamid Co | Sulphonamide blood complement inhibitors |
| US4119784A (en) * | 1977-07-01 | 1978-10-10 | American Cyanamid Company | Anionic substituted sulfonamido biphenyls |
| DE3000519A1 (de) | 1979-02-01 | 1980-08-14 | Byk Gulden Lomberg Chem Fab | Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
| DE3535167A1 (de) * | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| CA2154103C (en) * | 1995-07-18 | 1998-02-24 | Samuel Simon Asculai | Treatment of mucous membrane disease, trauma or condition and for the relief of pain |
| SK56798A3 (en) | 1995-10-30 | 1998-12-02 | Smithkline Beecham Corp | Protease inhibitors, pharmaceutical composition containing them and their use |
| US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| JP2001527513A (ja) | 1996-03-15 | 2001-12-25 | デュポン ファーマシューティカルズ カンパニー | スピロ環インテグリン阻害剤 |
| CZ16899A3 (cs) | 1996-07-22 | 1999-08-11 | Monsanto Company | Thiolsulfonamidové inhibitory metaloproteázy |
| US6130231A (en) | 1996-11-27 | 2000-10-10 | Dupont Pharmaceuticals | Integrin receptor antagonists |
| US6214834B1 (en) | 1997-03-28 | 2001-04-10 | Dupont Pharmaceuticals Company | Integrin inhibitor prodrugs |
| WO1998050342A1 (en) | 1997-05-08 | 1998-11-12 | Smithkline Beecham Corporation | Protease inhibitors |
| EP0877019B1 (de) | 1997-05-09 | 2001-12-12 | Hoechst Aktiengesellschaft | Substituierte Diaminocarbonsäuren |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| HUP0100520A3 (en) | 1998-01-23 | 2002-11-28 | Genentech Inc | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| CA2318145C (en) | 1998-02-04 | 2009-10-27 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| JPH11246527A (ja) | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Ｍｍｐ−８阻害剤 |
| DE19815547C1 (de) | 1998-04-07 | 1999-12-02 | Joachim Schmidt | Haftmittel für Zahnprothesen |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| WO2001070720A2 (en) * | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Carbocyclic side chain containing, n-substituted metalloprotease inhibitors |
| US6723733B2 (en) | 2000-05-19 | 2004-04-20 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
| WO2002060867A2 (en) | 2001-01-29 | 2002-08-08 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| WO2002074298A1 (en) | 2001-03-21 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Il-6 production inhibitors |
| EP1431267A4 (en) | 2001-08-09 | 2004-12-22 | Ono Pharmaceutical Co | COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT |
| GB0126157D0 (en) | 2001-10-31 | 2002-01-02 | Univ Aberdeen | Therapeutic compounds |
| WO2003080042A1 (en) | 2002-03-27 | 2003-10-02 | Shionogi & Co., Ltd. | Decomposition inhibitor for extracellular matrix of cartilage |
| EP1537116B1 (en) | 2002-09-04 | 2010-06-02 | Schering Corporation | Pyrazolopyrimidines suitable for the treatment of cancer diseases |
| DE10251170A1 (de) | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004073619A2 (en) * | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| US7572825B2 (en) | 2003-05-07 | 2009-08-11 | The University Court Of The University Of Aberdeen | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions |
| JPWO2004106290A1 (ja) | 2003-05-14 | 2006-07-20 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| GB0324792D0 (en) * | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| AU2004305321A1 (en) | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| GB0405193D0 (en) | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| JP2007536348A (ja) | 2004-05-05 | 2007-12-13 | ノボ ノルディスク アクティーゼルスカブ | スルホンアミド誘導体 |
| GB0412553D0 (en) | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| WO2006134467A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | N-(pyridin-2-yl)-sulfonamide derivatives |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| TW200720261A (en) | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
| WO2007089335A2 (en) * | 2005-12-29 | 2007-08-09 | Lexicon Pharmaceutical Inc. | Multicyclic amino acid derivatives and methods of their use |
| GB0705400D0 (en) * | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
-
2008
- 2008-09-19 GB GBGB0817208.2A patent/GB0817208D0/en not_active Ceased
-
2009
- 2009-09-18 EP EP09785123.2A patent/EP2349990B8/en active Active
- 2009-09-18 WO PCT/GB2009/002223 patent/WO2010032010A1/en not_active Ceased
- 2009-09-18 ES ES09785123.2T patent/ES2675074T3/es active Active
- 2009-09-18 CA CA2736980A patent/CA2736980C/en active Active
- 2009-09-18 JP JP2011527395A patent/JP5840492B2/ja active Active
- 2009-09-18 US US13/063,950 patent/US8207167B2/en active Active
- 2009-09-18 DK DK09785123.2T patent/DK2349990T3/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502965A5 (enExample) | ||
| JP2012502964A5 (enExample) | ||
| HRP20150839T1 (hr) | Spojevi aril-fenil-sulfonamido-cikloalkila i njihova uporaba | |
| JP6721499B2 (ja) | 骨の成長を促進するためのアルキルアミンハルミン誘導体 | |
| CA2701959C (en) | Inhibitors of kinase activity | |
| CN101678014B (zh) | 杂环激酶调节剂 | |
| JP2020508302A5 (enExample) | ||
| JP2020528905A5 (enExample) | ||
| TW201808936A (zh) | 吡咯并苯并二氮呯類及其共軛物 | |
| JP2013536807A5 (enExample) | ||
| BR112017027414B1 (pt) | Derivados hidroxiéster, processo para prepará-los e composições farmacêuticas os contendo | |
| JP2023515629A (ja) | Ｃｄｋ２／４／６阻害剤としての化合物 | |
| CN110167941B (zh) | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 | |
| JP5775304B2 (ja) | ガンの治療のためのイミダゾ［１，２−ａ］キノキサリンおよび誘導体 | |
| JP2012525329A5 (enExample) | ||
| MX2010013699A (es) | Derivados de azacarbolinas, su preparacion y su uso terapeutico. | |
| ES2890552T3 (es) | Compuestos de pirimidina sustituidos y su uso como inhibidores de SYK | |
| EP2145877A2 (en) | Aurora Kinase inhibitors | |
| CA2556768A1 (en) | Piperidinyl targeting compounds that selectively bind integrins | |
| BR112020009290A2 (pt) | derivados de pirimidina para a prevenção e tratamento de infecções bacterianas | |
| WO2023040996A1 (zh) | 氮杂吲唑大环化合物及其用途 | |
| BR112019025866A2 (pt) | compostos e composições para indução de condrogênese | |
| CN102260258A (zh) | 吡啶并[2，3-d]嘧啶衍生物，它们的制备，在治疗中的用途 | |
| US8278450B2 (en) | Kinase inhibitors | |
| AU2004298907B2 (en) | Use of a compound having two gold (I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold (I) atoms for the treatment of cancer |